It’s been an exciting and hopeful past couple of weeks in the world of COVID-19 vaccine news. On December 11, the Food and Drug Administration issued an emergency use authorization for a two-part novel coronavirus vaccine produced by Pfizer-BioNTech, and over half a million doses were administered in that first week. On December 18, the FDA issued emergency authorization for a second vaccine produced by Moderna.
This good news isn’t without a few bumps in the road. Shipments of Pfizer’s vaccine have been delayed and piled up in warehouses as the company awaits instructions on where to send them, and states have been told to expect to receive fewer doses than had originally been planned.
There have also been a few stories about people who have had allergic reactions after receiving the vaccine. When stripped from context, these stories can come off as unnecessarily alarming.
The public has a right to know about problems with the vaccine rollout, and journalists have a responsibility to take extra care to not induce unwarranted panic.
Last Wednesday, The New York Times published an article about two health care workers in Alaska who had a negative reaction to Pfizer’s vaccine. The story itself is a straightforward report and includes some helpful context for readers. One of the two workers experienced puffy eyes, lightheadedness, and a scratchy throat, but was treated and released within an hour. The other worker’s story was more serious and included a short stay in the hospital’s intensive care unit.
Importantly, the Times noted that the hospital had administered 144 doses and added that both workers still supported the vaccine and didn’t want their reactions to impact others’ abilities to get it.
Where the Times may have erred, however, is how it presented the story to the public. People subscribed to the newspaper’s push notifications received an alert as soon as the article was published. “A health worker in Alaska had a serious allergic reaction after getting Pfizer’s vaccine,” it read. “It’s unclear if the case has broader safety implications."